StockData

Fulcrum Therapeutics vs Septerna

FULC and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FULC and SEPN compare

Septerna is the larger company, worth 6.5 times as much as Fulcrum Therapeutics ($1.9B against $286M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFULCSEPN
Size and price
Market cap$286M$1.9B
Share price$3.75$40.02
Change, 1 year−56.6%72.0%
Change, 5 years−75.1%–
Beta (5Y)1.360.70
Employees55130
StockData Score
Total score88
Valuation score1 (better)0
Growth score01 (better)
Performance score11
Health score66
Dividend score00
Valuation
P/S–19.4×
P/B0.9× (better)4.4×
FCF yield−23.1%−4.2% (better)
Fair value–$15.08
Margin of safety–−165%
Growth
Revenue growth (TTM)–337%
Profitability
Operating margin–−76.2%
Net margin–−61.3%
FCF margin–−80.6%
Return on equity−32.4%−14.4% (better)
Return on invested capital−35.0%–
Financial health
Debt / equity0.000.00
Current ratio31.35 (better)4.84
Altman Z-score10.37 (better)5.91
Piotroski F-score35 (better)
Dividends and buybacks
Buyback yield−1.5%–
Shareholder yield−1.5%0.00% (better)
Ownership
Held by institutions112%102%
Held by insiders34.7%27.9%
Insider net buying, 12 months−$57.5M (better)−$80.9M
Short interest, % of float12.9%10.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.